The future of the industry may be defined less by legalization than by classification.
For years, the cannabis industry has focused on one question: Is cannabis legal or illegal? That debate has shaped investment decisions, business strategy and public policy for more than a decade.
Increasingly, however, Washington is answering a different question: Which cannabis-derived product are we talking about?
That distinction may become one of the industry's defining challenges.
Products derived from the cannabis plant are no longer moving toward a single regulatory framework. Instead, they are being sorted into distinct legal, commercial and operational categories. Depending on a product's cannabinoid content, intended use, manufacturing process and marketing claims, it may be treated as a Schedule III prescription medication, state-licensed medical marijuana, state-licensed adult-use marijuana, federally defined hemp, a hemp-derived cannabinoid product, a consumer wellness product or, in some states, an intoxicating beverage.
The result is an industry becoming more fragmented, not more standardized. That shift has implications well beyond public policy. It affects banking, lending, taxation, insurance, product development, investment and long-term business strategy.
The cannabis industry already operates under a patchwork of regulations. That complexity is growing once again.
Consider today's marketplace.
A physician may prescribe an FDA-approved cannabinoid medication dispensed through a traditional pharmacy. A qualifying patient may obtain physician-recommended medical marijuana through a state medical cannabis program. An adult consumer may purchase marijuana from a licensed adult-use dispensary. In states where permitted, another consumer may purchase a hemp-derived THC beverage through traditional retail channels. Someone else may order a CBD wellness product online.
To many consumers, these all feel like cannabis products. Operationally, they increasingly are not. Each category may be governed by different statutes, regulators, licensing requirements, tax treatment and commercial expectations. Depending on the product, oversight may involve agencies such as the DEA, FDA, USDA and in certain product categories, the Alcohol and Tobacco Tax and Trade Bureau (TTB), alongside state cannabis, health or alcohol regulators. These distinctions influence far more than compliance. They shape manufacturing, distribution, banking relationships, insurance, financing and investment decisions.
Cannabis business operations will become more complex.
The most significant consequence may not be that the industry becomes more regulated. It may be that individual businesses become more operationally complex.
Consider a multi-state operator with cultivation, manufacturing and retail operations across several states. Some facilities may serve medical markets while others serve adult-use markets. The company may operate under different licensing structures, manufacture different product formulations, distribute branded products through wholesale channels in some states while selling directly to consumers in others, and rely on shared finance, compliance, treasury, HR and executive teams across the enterprise.
What appears to be one company may actually operate across dozens of distinct regulatory environments. Revenue streams, inventory, manufacturing, facilities, licenses, distribution channels, financial reporting, compliance programs and internal controls may all need to account for multiple regulatory classifications operating simultaneously.
That complexity is compounded by uncertainty. As federal policy continues to evolve, many of the operational expectations that could accompany broader federal involvement have yet to be defined. Federal oversight is also unlikely to replace existing state regulatory frameworks. More likely, it will layer onto them, requiring businesses to adapt as new expectations are introduced and interpreted over time.
For many organizations, the challenge will be building operating models capable of functioning across multiple regulatory environments while maintaining consistent governance, financial controls and compliance oversight.
Cannabis banking and finance will become more complex.
Financial institutions face a parallel challenge.
Banks are evaluating cannabis organizations that may span multiple legal entities, business lines, product categories, and revenue streams across evolving regulatory classifications. What once appeared straightforward, including product classification, regulatory applicability, and risk assessment, is becoming increasingly complex as businesses diversify and regulatory frameworks continue to evolve.
That complexity influences onboarding, and enhanced due diligence, ongoing monitoring, lending, insurance, audits and enterprise risk management.
For years, many assumed federal reform would simplify cannabis banking.
It may simplify certain legal questions. Operationally, however, it could have the opposite effect by introducing additional regulatory frameworks.
Preparing for what's next
The future of cannabis may be defined by multiple regulatory ecosystems operating alongside one another, with businesses increasingly expected to navigate several at the same time.
The organizations best positioned for that future won't necessarily be those making the best predictions about federal policy. They'll be the ones building flexible operating models, disciplined governance and scalable compliance programs capable of adapting as the regulatory landscape continues to fragment.
The cannabis industry has spent more than a decade preparing for legalization. But the organizations that thrive over the next decade may be the ones best prepared to pivot and operationalize around the complexities of regulatory fragmentation.
Disclaimer: This article is intended for informational and educational purposes only and reflects Safe Harbor's analysis of current industry trends and regulatory developments as of the publication date. It does not constitute legal, tax, regulatory or financial advice. Laws, regulations and agency guidance continue to evolve, and readers should consult qualified legal, tax and compliance professionals regarding their specific circumstances.